Global News

OPKO, Pfizer ink global agreement for human growth hormone

Monday, December 15, 2014 12:39 PM

OPKO Health, a multinational biopharmaceutical and diagnostics company, and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO's long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age.

More... »


Sosei acquires Jitsubo, a Japanese peptide technology company

Monday, December 15, 2014 12:37 PM

Sosei Group, a global biopharmaceutical company of Japanese origin, will acquire all existing shares of and underwrite a third-party allocation of new shares of Jitsubo, a Japanese peptide technology company. Jitsubo will become a consolidated subsidiary of the group.

More... »


Bill & Melinda Gates Foundation awards grant to Fio for Ebola diagnostics

Monday, December 15, 2014 12:36 PM

Fio has received a grant financed by the Bill & Melinda Gates Foundation to adapt its Fionet solution to connect rapid diagnostics and data in the fight against Ebola. Headquartered in Toronto, Canada, Fio's solution combines mobile intelligent devices with cloud information services to create a healthcare delivery solution that drives, rather than competes with, data capture.

More... »

Congress includes $25 million increase for Alzheimer’s research funding in spending bill

Monday, December 15, 2014 12:33 PM

The 2015 U.S. government spending package, known as the cromnibus, includes an increase of $25 million for the National Institute on Aging (NIA), with an expectation that much of the funding would support additional research into Alzheimer’s and dementia.

More... »

Janssen Therapeutics, USAID collaborate on antimicrobial resistance

Monday, December 15, 2014 12:32 PM

Janssen Therapeutics, a Johnson & Johnson affiliate, has signed a memorandum of understanding (MOU) with the U.S. Agency for International Development (USAID) to step up the fight against the health threat of antibiotic-resistant bacteria.

More... »

DaVita business units DaVita Clinical Research, HealthCare Partners Clinical Research to merge

Monday, December 15, 2014 12:29 PM

DaVita HealthCare Partners, a U.S. innovative healthcare community, has announced that two of its business units, DaVita Clinical Research (DCR) and HealthCare Partners Clinical Research, will merge capabilities to further expand its clinical research and data analytics services, specifically in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), as well as primary care and chronic disease patients treated in an integrated care organization.

More... »

Human interaction is still vital, even with new technology trends in clinical trials

Monday, December 15, 2014 08:00 AM

Healthcare technology has evolved and has created efficiencies in a variety of healthcare settings.

More... »

CRF Health boosts leadership team with new appointments

Monday, December 15, 2014 08:00 AM

CRF Health, a Plymouth Meeting, Pa.-based global provider of eCOA solutions for the life sciences Industry, has announced two new additions to the company's executive leadership team as the organization continues to invest in a deeper and broader management structure to position the business for future growth.

More... »

Anergis starts phase II trial with birch pollen allergy vaccine AllerT

Monday, December 15, 2014 08:00 AM

Anergis, a Swiss-based company developing proprietary ultra-fast allergy vaccines, has begun a phase II trial designed to finalize the dose selection for the phase III study of AllerT. AllerT is Anergis´ lead vaccine against birch pollen allergy that originated from the company´s proprietary Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceutical-grade, long-peptide immunotherapeutics designed for an ultra-fast, safe and long-lasting treatment of allergy patients.

More... »

ALS Association awards research funds for C9orf72 clinical trials

Friday, December 12, 2014 03:34 PM

The ALS Association, a national nonprofit organization based in Wash. D.C., has awarded $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs